The transparency discussion is undermined by the fixation on outcomes and the focus on publishing information that realistically adds almost nothing to the community's understanding of how medicines are funded in Australia. This fixation is compounded by a power imbalance that sees all the pressure on the industry when it comes to transparency while 'backroom' processes remain a mysterious locked box.
Transparency of process is more important than transparency of outcome
January 23, 2020 Latest NewsCommentNews of the Day
Latest Video
New Stories
-
LifeSciences Australia honours outstanding professionals at MTP Sector Awards 2026
June 12, 2026 - - Latest News -
'The changes could cause irreversible damage to our vibrant and world-leading biotech, medtech and health tech sector'
June 12, 2026 - - Australian Biotech -
The opportunity to change the conversation, the negotiating dynamic, and take some control
June 12, 2026 - - Latest News -
State and Territory ministers warn against centralising NDIS power
June 12, 2026 - - Latest News -
ARCS evolves into LifeSciences Australia as part of wider strategic change
June 11, 2026 - - Latest News -
Sigma confirms interest in the acquisition of UK pharmacy chain Boots
June 10, 2026 - - Latest News -
Island secures US partnership to advance Galidesivir dose study for Marburg
June 10, 2026 - - Australian Biotech

